{"id":47890,"date":"2022-03-18T13:46:15","date_gmt":"2022-03-18T13:46:15","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&#038;p=47890"},"modified":"2022-03-18T13:46:15","modified_gmt":"2022-03-18T13:46:15","slug":"benjamin-a-weinberg-asco-gi22-pivotal-studies-in-colorectal-cancer","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/colorectal-cancer\/conference-hub\/benjamin-a-weinberg-asco-gi22-pivotal-studies-in-colorectal-cancer\/","title":{"rendered":"Benjamin A Weinberg, ASCO GI22: Pivotal Studies in Colorectal Cancer"},"content":{"rendered":"<p><b>Professor Benjamin A Weinberg<\/b><span style=\"font-weight: 400\"> (<\/span><span style=\"font-weight: 400\">Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) summarises key data from pivotal studies in colorectal cancer that<\/span><span style=\"font-weight: 400\"> were presented at the ASCO Gastrointestinal Cancers Symposium 2022.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">GALAXY study in CIRCULATE-Japan abstract: <\/span><a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.4_suppl.009\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.4_suppl.009<\/span><\/a><span style=\"font-weight: 400\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\">Clinical trial information: jRCT1031200006<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">RESPECT study abstract: <\/span><a href=\"https:\/\/meetings.asco.org\/abstracts-presentations\/204531\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">https:\/\/meetings.asco.org\/abstracts-presentations\/204531<\/span><\/a><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\">Clinical Trial Registration Number: UMIN000008866<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">GERCOR NIPICOL study abstract: <\/span><a href=\"https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.4_suppl.013\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.4_suppl.013<\/span><\/a><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\">Clinical trial information: NCT033501260.<\/span><\/p>\n<p><strong>Questions<\/strong><\/p>\n<ol>\n<li><span style=\"font-weight: 400\">\u00a0 \u00a0 \u00a0 \u00a0 \u00a0What has the GALAXY study taught us about ctDNA dynamics and clinical outcomes in the management of patients with resectable colorectal cancer (CRC)? (00:15-01:45)<\/span><\/li>\n<li><span style=\"font-weight: 400\"> \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Following the RESPECT study, what should be the preferred first-line treatment for patients with metastatic (m)CRC aged 75+? (01:45-03:30)<\/span><\/li>\n<li><span style=\"font-weight: 400\"> \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 According to the latest GERCOR NIPICOL data, when is the best time to stop immunotherapy in patients with microsatellite instability-high\/mismatch repair deficient mCRC? (03:30-05:01)<\/span><\/li>\n<li><span style=\"font-weight: 400\"> \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 What have we learned about the use of neoadjuvant dostarlimab for MSI-H locally advanced CRC? (05:01-06:10)<\/span><\/li>\n<li><span style=\"font-weight: 400\"> \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 What is the potential of BEACON plus nivolumab for BRAF V600E mutated mCRC? (06:10-07:52)<\/span><\/li>\n<\/ol>\n<p><b>Speaker Disclosure<\/b><span style=\"font-weight: 400\">: Benjamin A Weinberg has no conflicts of interest to declare in relation to this video.<\/span><\/p>\n<p><b>Support<\/b><span style=\"font-weight: 400\">: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.<\/span><\/p>\n<p><em><span style=\"font-weight: 400\">Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.<\/span><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) summarises key data from pivotal studies in colorectal cancer that were presented at the ASCO Gastrointestinal Cancers Symposium 2022. GALAXY study in CIRCULATE-Japan abstract: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2022.40.4_suppl.009\u00a0 Clinical trial information: jRCT1031200006 RESPECT study abstract: https:\/\/meetings.asco.org\/abstracts-presentations\/204531 Clinical Trial Registration Number: UMIN000008866 GERCOR NIPICOL study abstract: [&hellip;]<\/p>\n","protected":false},"featured_media":47891,"template":"","class_list":["post-47890","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-colorectal-cancer","vocabulary_1-gastrointestinal-cancers"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/47890"}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":1,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/47890\/revisions"}],"predecessor-version":[{"id":47892,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/47890\/revisions\/47892"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/47891"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=47890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}